Technology

Technology

Our Platform 

A foundation for developing novel therapies for genetic diseases

Castle Creek Biosciences’ autologous fibroblast technology uses our patented manufacturing process, which involves collecting small skin biopsies from patients, isolating cells and expanding them in culture, transducing the fibroblast cells with an integrative lentiviral vector to express a targeted protein, followed by continued expansion of the gene-modified cells in culture. The cells are then locally administered to the disease site with the goal of expressing the target protein in the desired region in order to restore its functionality. As part of this process, Castle Creek Biosciences also creates a personalized cell bank of genetically modified autologous fibroblasts that can be stored cryogenically, serving as a repository for the patient’s long term drug product needs.